SCHEMBL5161349

SCHEMBL5161349

NC(=O)CC(=O)c1cnc[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC1 P19801 1/20 0.47
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
TP53 P04637 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KMT2A Q03164 3/20 0.42
HRH3 Q9Y5N1 3/20 0.41
QPCT Q16769 1/20 0.41
QPCTL Q9NXS2 1/20 0.41
CYP3A4 P08684 4/20 0.41
TSHR P16473 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 3/20 0.40
GABRA1 P14867 1/20 0.40
NFKB1 P19838 1/20 0.40
GABRR1 P24046 1/20 0.40
GABRR2 P28476 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8820702 0.84 NPC1 (0.47) AOC1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL2827683 0.80
SCHEMBL5164175 0.78 TP53 (0.42) AOC1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL5164308 0.78 TP53 (0.48) AOC1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL826324 0.77
SCHEMBL5160020 0.77 TP53 (0.41) AOC1NPC1RAB9ATP53SMN1; SMN2
SCHEMBL23124259 0.76
SCHEMBL5217908 0.76
Hydrochloric Acid SCHEMBL29686657 0.75 AOC1 (0.48) AOC1NPC1RAB9ATP53SMN1; SMN2
Hydrochloric Acid SCHEMBL17843027 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO AOC1 867/4885NPC1 2400/4885RAB9A 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.